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FNAAbstract Myeloid sarcoma is a rare extramedullary myeloid tumor typically occurring in associa-
tion with acute myeloid leukemia.
We report an atypical case of myeloid sarcoma arising from the rib of a healthy young man with no
speciﬁc blood test abnormalities.
Once the malignant nature of the tumor was conﬁrmed, a complete surgical excision was performed
and deﬁnitive diagnosis was achieved by way of an exhaustive histopathological examination of
surgical specimens.
Systemic treatment was administered and currently neither systemic nor local relapse has been
identiﬁed. Our experience suggests surgical resection could be a valid treatment in isolated myeloid
sarcoma patients.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. All rights reserved.1. Introduction
Myeloid sarcoma is an extramedullary myeloid blast cell
tumor manifesting with solid masses usually occurring during
onset of acute myeloid leukemia, but seldom manifesting with
no myeloproliferative disorder.
2. Case
A 30-year-old man was admitted to our Institution, Monaldi
Hospital, in March 2013 with a left hemithorax pain arisen
almost six months before.ed.
Fig. 2 MPR (multi planar reconstruction) of MDCT in Fig 1.
The fracture of the VII rib appears more evident.
Fig. 3 Contrast-Enhanced MDCT axial scan. The mean atten-
uation value of the pathologic tissue is 127 HU.
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eupnoeic with normal heart rate and blood pressure; his med-
ical history was unremarkable.
On physical exam, the chest was asymmetric because of a
painful swelling on left mid axillary line; no abnormality on
percussion and auscultation were found. The rest of the sys-
temic examination was normal.
Routine blood tests showed a mild neutrophilia with nor-
mal WBC count; RBC, HGB, PLTs, ESR were within normal
range; serum for HBsAg and HCV were negative.
A radiographic exam of the chest revealed the presence of a
lytic seventh rib lesion associated with thinning and expansion
of cortical bone; a non-contrast CT scan lets identify a 45 mm
soft tissue mass growing from the bone marrow up to fracture
the cortical bone and envelop the arc all around (Figs. 1 and 2).
A whole body contrast-enhanced CT scan showed the
pericostal mass to have a great homogeneous enhancement;
the parietal pleura appeared thickened, but no lung inﬁltra-
tion was identiﬁed; no other abnormalities were observed
(Fig. 3).
The patient underwent an ultrasound-guided ﬁne needle
aspiration (FNA) in order to perform a cytological exam of
the pericostal mass from which, however, only normal stromal
and inﬂammatory cells could be identiﬁed.
A 18-FDG PET-CT scan revealed the pericostal mass to
have an intense metabolic activity with a 13,49 SUV (Fig. 4);
the patient underwent a CT-guided TRU-CUT biopsy of the
mass and through the histological examination of the sample
it has been possible to recognize a pattern of myeloid or lym-
phoid malignant neoplasm with strong muscle and bone inﬁl-
tration by granulocytes and lymphocytes (Fig. 5).
The patient was transferred to the thoracic surgery depart-
ment where he underwent thoracectomy for tumor resection.
Surgical resection of the mass was performed either to achieve
a pain palliation than to allow precise and accurate diagnosis.
The pathologic mass and the seventh left fractured rib have
had to be resected together with the sixth and eighth rib. Tho-
racic surgeons have then performed a prosthetic reconstruction
of the chest wall. The chest pain improved postoperatively.
The histopathological examination of the surgical speci-
mens identiﬁed an invasive tumor of seventh rib with differentFig. 1 MDCT axial scan of the soft tissue mass. A soft tissue
mass originating from the bone marrow of the VII left rib has
grown up to fracture the cortical bone and envelope the rib. The
pathologic tissue has a mean attenuation value of 34.9 HU.
Fig. 4 18FDG PET scan. The image shows the high radionu-
clide concentration in the pathologic tissue.
Fig. 5 CT guided TRU-CUT. The cutting needle is inside the
pathologic tissue surrounding the rib.
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inﬁltration. Immunohistochemical stains have been essential
to achieve the ﬁnal diagnosis of differentiated myeloid sarcoma
(Figs. 6 and 7).
The patient underwent bone marrow biopsy from which no
abnormalities were identiﬁed.Fig. 6 Immunohistochemical stain. A, Hematoxilin&Eosin; B,As recommended in myeloid sarcoma patients with or with-
out a concomitant acute myeloid leukemia, a conventional
AML treatment protocol was administered.
The patient was included in a follow up program and, cur-
rently, neither myeloproliferative disorders nor local relapse
has been identiﬁed.
3. Discussion
Myeloid sarcoma was described ﬁrst in 1811 by British physi-
cian Allan Burns and over years it has been addressed as chlo-
roma, granulocytic sarcoma, extramedullary myeloid tumor or
extramedullary acute myeloid leukemia (1).
Since 2008, myeloid sarcoma has been deﬁned a separate
pathologic entity in WHO Classiﬁcation of Myeloid Neoplasm
described as ‘‘myeloid blasts with or without maturation that
grow to form a tumor mass with effacement of tissue architec-
ture’’ in contrast with a leukemic inﬁltrate which shows differ-
ent pathologic features (2).
Myeloid sarcoma is mostly identiﬁed during onset or
relapse of acute myeloid leukemia (AML), even though it
can occurs as isolated leukemic tumor and precedes the
appearance of hematopoietic disorders by months or years.
In few cases, myeloid sarcoma has been described associated
with myeloproliferative neoplasms other than AML or with
a myelodysplastic syndrome (3).Vimentin; C, CD-4; D: Leukocyte Common Antigen (LCA).
Fig. 7 Immunohistochemical stain. A, Hematoxilin&Eosin; B, Lysozyme; C, CD-68; D, CD-43; E, CD-15; F, Myeloperoxidase (MPO).
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AML with an increased incidence after an allogeneic stem cell
transplantation; sex and age prevalence are not clear with cases
reported in 1 to 81 year old patients; tumor dimension at
presentation is highly variable, usually ranging from 20 to
200 mm (4–6).
Pathogenesis is poorly understood: homing signals aber-
rance and matrix metalloproteinases over-expression have
been supposed to preclude bone marrow localization and pro-
mote extra-medullary tissue inﬁltration (7).
According to the cell differentiation grade, myeloid sar-
coma is classiﬁed as mature, immature or blastic as well,
according to the most expressed cell lineage, it is classiﬁed as
granulocytic, monoblastic or myelomonocytic. Myeloid sar-
coma commonly involves bone, skin and lymph nodes,
although it has been reported to involve central nervous sys-
tem, paranasal sinuses, breast, chest wall, pleura, lung and ret-
roperitoneum. Usually asymptomatic, so that over 50% of
cases has only autoptic evidence, myeloid sarcoma can give rise
to signs and symptoms like bleeding and pain related to com-
pressive effects of a growing mass (3).
Myeloid sarcoma is often initially misdiagnosed for lym-
phoma, anaplastic cancer, melanoma, extramedullary hemato-
poiesis or inﬂammation (8).
In affected or previously treated AML patients, the onset of
a soft tissue mass imposes to consider myeloid sarcoma along
with infections, hemorrhages and secondary neoplasms as a
possible diagnosis. Imaging features are effective in differenti-
ating synovitis, arthritis, hematoma and abscess from myeloid
sarcoma, although these are nonspeciﬁc and overlapping with
further diseases (e.g. neuroblastoma or PNETs in children and
metastasis, lymphoma or osteomyelitis in adults). In patients
without myeloid neoplasm nor a myelodysplastic syndrome,
onset of a soft tissue mass often requires biopsy and extensive
histochemical examination to achieve a correct diagnosis (6,8).4. Conclusions
Even though in patients with acute myeloid leukemia soft tis-
sue masses can have both malignant and benign nature, mye-
loid sarcoma must always be suspected in these ones.
Diagnosis of myeloid sarcoma is unexpected in patients
with no evidence of myeloproliferative disorder and in this cir-
cumstance the diagnosis is performed by biopsy of the tumor.
MDCT is the ﬁrst choice imaging modality, useful in detecting
lesions, in deﬁning disease extension for other treatment
modalities (radiation therapy) and in a proper management
and follow up of the patients. Optimal treatment is not
deﬁned: surgery can be a choice in tumors giving pain or organ
dysfunction; systemic treatment has to be considered in order
to prevent relapses and progression to acute myeloid leukemia;
hematopoietic stem cell transplantation has to be considered in
relapsed disease, even without bone marrow involvement;
radiotherapy can be used in patients with relapsed disease,
organ dysfunction, poor responder to systemic treatment or
unsuitable for surgery (9,10).
Myeloid sarcoma is an uncommon occurrence that requires
a precise diagnosis because its treatment takes more advantage
than antiblastic drugs.
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